Clinical Trial Update: Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for long-term continuous infusion ch14.18/CHO plus subcutaneous Aldesleukin (IL-2) in Neuroblastoma (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Aldesleukin (IL-2) (Aldesleukin)
• long term continuous infusion ch14.18/CHO

Snippet

Sponsor: St. Anna Kinderkrebsforschung | Conditions: Neuroblastoma | Phase 1, Phase 2 | Status: UNKNOWN